TriangleIn-111 rosopatamab tetraxetan (NCT06549465)
In-111 rosopatamab tetraxetan trial for PSMA PET-Positive Castration-Resistant Prostate Cancer (NCT06549465). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with progressive, PSMA-positive metastatic castration-resistant prostate cancer after androgen deprivation and an androgen-receptor signaling inhibitor. Prior treatment determines which study part may fit.
The idea: use an antibody to carry actinium-225 radiation to PSMA-bearing cells. Researchers test different doses and an extended regimen. Some participants first receive an indium-111 imaging dose. One part requires prior lutetium-177 PSMA therapy; other parts exclude it. Prior platinum chemotherapy or PARP inhibitors are excluded throughout.
This phase 2 study plans 93 patients. Convergent Therapeutics sponsors eight recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.